Caption Management LLC Invests $464,000 in Bausch + Lomb Co. (NYSE:BLCO)

Caption Management LLC bought a new position in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 25,674 shares of the company's stock, valued at approximately $464,000.

Several other institutional investors have also bought and sold shares of the stock. Barclays PLC acquired a new stake in Bausch + Lomb during the 3rd quarter valued at $5,797,000. Raymond James Financial Inc. bought a new stake in shares of Bausch + Lomb during the fourth quarter worth $2,844,000. Renaissance Technologies LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter valued at $372,000. Ellsworth Advisors LLC bought a new position in shares of Bausch + Lomb in the fourth quarter valued at about $665,000. Finally, Renaissance Capital LLC lifted its position in Bausch + Lomb by 116.2% during the 4th quarter. Renaissance Capital LLC now owns 94,182 shares of the company's stock worth $1,701,000 after buying an additional 50,622 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Trading Down 2.3 %

NYSE:BLCO traded down $0.27 during mid-day trading on Friday, hitting $11.23. The company had a trading volume of 657,304 shares, compared to its average volume of 648,895. The firm has a market cap of $3.97 billion, a P/E ratio of -12.34, a P/E/G ratio of 0.85 and a beta of 0.58. Bausch + Lomb Co. has a fifty-two week low of $10.45 and a fifty-two week high of $21.69. The business's fifty day moving average is $13.45 and its two-hundred day moving average is $16.59. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The firm had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the business earned $0.07 EPS. The firm's revenue was up 3.5% compared to the same quarter last year. As a group, research analysts expect that Bausch + Lomb Co. will post 0.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BLCO. HC Wainwright dropped their target price on shares of Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company reduced their price objective on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Evercore ISI decreased their price objective on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research report on Thursday, May 1st. Morgan Stanley dropped their target price on Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a research report on Tuesday. Finally, Citigroup decreased their price target on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating on the stock in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $15.50.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.